Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer
暂无分享,去创建一个
Wei Zhang | Jing Liu | Chao Zhang | Dan Zhao | Wenya Zhao | Zhaogang Yang | Wei Zhang | J. Rao | Jing Liu | Zhaogang Yang | Junfeng Shi | Liliang Jin | Junfeng Shi | Liliang Jin | Xiaobing Wang | Haimei Tian | Yanfen Li | Mo Li | Teng Wang | Aili Zhang | Di Shen | Cuining Zheng | Jun Qi | Jianyu Rao | J. Qi | Aili Zhang | Chao Zhang | Mo Li | Hai-mei Tian | Dan Zhao | Xiaobing Wang | D. Shen | Teng Wang | Yan-fen Li | Cuining Zheng | Wenya Zhao | L. Jin
[1] M. Duffy,et al. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.
[2] Zhiping Luo,et al. A multifunctional nanoparticulate theranostic system with simultaneous chemotherapeutic, photothermal therapeutic, and MRI contrast capabilities , 2016 .
[3] Li-ping Guo,et al. Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy , 2014, Cancer science.
[4] L. Påhlman,et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer , 2011, British Journal of Cancer.
[5] Wei Zhang,et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma , 2014, BMC Cancer.
[6] W. D. Fairlie,et al. MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.
[7] J. M. Kim,et al. NAG-1/GDF15 Transgenic Mouse Has Less White Adipose Tissue and a Reduced Inflammatory Response , 2013, Mediators of inflammation.
[8] Mark P Purdue,et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. , 2012, The New England journal of medicine.
[9] Wei Zhang,et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer , 2016, Journal of cellular and molecular medicine.
[10] G. Young,et al. Screening for colorectal cancer: alternative faecal occult blood tests. , 1998, European journal of gastroenterology & hepatology.
[11] K. Søreide,et al. And Acrobaticc Collaborators , 2022 .
[12] W. D. Fairlie,et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] H. Brenner,et al. Long-term risk of colorectal cancer after negative colonoscopy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Andrew Tsourkas,et al. A pH-Responsive Drug-Delivery Platform Based on Glycol Chitosan-Coated Liposomes. , 2015, Small.
[15] E. Giovannucci,et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. , 2014, Journal of the National Cancer Institute.
[16] S. Vukicevic,et al. Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.
[17] J. L. Aguayo-Albasini,et al. Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme. , 2016, Cancer epidemiology.
[18] U. Ladabaum,et al. Comparative Effectiveness and Cost-Effectiveness of Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies , 2013, The American Journal of Gastroenterology.
[19] F. Chan,et al. Asia Pacific consensus recommendations for colorectal cancer screening , 2008, Gut.
[20] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[21] J. Niu,et al. Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma , 2015, PloS one.
[22] R. Anwar. Screening for colorectal cancer in the UK. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] L M Schuman,et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.
[24] C. Lepage,et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[25] N. Kim,et al. Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels , 2009, Annals of Surgical Oncology.
[26] D. McMillan,et al. Long-Term Follow-Up of Patients Undergoing Resection of TNM Stage I Colorectal Cancer: An Analysis of Tumour and Host Determinants of Outcome , 2016, World Journal of Surgery.
[27] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[28] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[29] J. Meyerhardt,et al. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. , 2015, Gastroenterology.
[30] K. Kinzler,et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] W. Khafagy,et al. Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients. , 2009, Hepato-gastroenterology.
[32] Y. Surh,et al. Resolution of inflammation as a novel chemopreventive strategy , 2013, Seminars in Immunopathology.
[33] Shung-Haur Yang,et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer , 2011, International Journal of Colorectal Disease.